NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety

Table 5 Boceprevir: clinical parameters

RCT	Dose frequency	Duration	SVR	Possible AE
SPRINT 1	12 pills for 3 intakes	28-wk triple therapy vs 4-wk lead-in phase	54%-56%	Metal taste, anemia
		48-wk triple therapy vs 4-wk lead-in phase	67%-75%
SPRINT 2	12 pills for 3 intakes	28-48 wk: ''viral response-based treatment''; ''lead-in period''; if HCV RNA (-) by week 8 and 24, to stop at week 28; if HCV RNA (+), 20 wk of double therapy	67% And 44% were given abridged AVT	Taste disturbances, anemia, neutropenia

AE: Adverse event; AVT: Antiviral treatment; HCV: Hepatitis C virus.